Navigo Proteins and Oncodesign Precision Medicine have entered a partnership focusing on the advancement of novel systemic radiotheranostic agents used in cancer treatment.
The partnership will leverage OPM's technologies and Navigo's proprietary Affilin platform to develop new treatments for resistant and metastatic cancers. The aim is to create radiotheranostic agents that can detect and destroy tumor cells, a method that's been clinically successful in treating specific types of cancers. The partnership will initially focus on two targets in oncology and develop molecules to the stage of drug candidates. The companies also aim to expand the partnership to additional targets.
Headquartered in Germany, Navigo Proteins is a biotechnology company specializing in protein engineering. Its focus is on developing precision affinity ligands and biotherapeutics. Navigo Proteins uses its proprietary platforms, Precision Capturing and Precision Targeting, to create custom affinity chromatography solutions and novel biotherapeutics, respectively.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.